| Hasan Ercan, MD | |
|
400 Highland Ave., Lewistown, PA 17044 | |
| (717) 248-5411 | |
| Not Available |
| Full Name | Hasan Ercan |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 400 Highland Ave., Lewistown, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982792354 | NPI | - | NPPES |
| 260634 | Other | PA | MEDICARE |
| PENDING | Other | FL | MEDICARE |
| PENDING | Medicaid | FL |
| Entity Name | Middlesex Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972563138 PECOS PAC ID: 5092611731 Enrollment ID: O20031216000592 |
News Archive
Johns Hopkins researchers and colleagues have found a previously unrecognized role for tiny hair-like cell structures known as cilia: They help form our sense of touch.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
While many different combinations of genetic traits can cause autism, brains affected by autism share a pattern of ramped-up immune responses, an analysis of data from autopsied human brains reveals. The study, a collaborative effort between Johns Hopkins and the University of Alabama at Birmingham, included data from 72 autism and control brains.
Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).
A RAND Corporation report funded by The Rockefeller Foundation shows that COVID-19 testing can be effectively integrated into K-12 schools' pandemic response plans, helping families and staff feel more comfortable with in-person instruction.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hasan Ercan, MD 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 271-6144 | Hasan Ercan, MD 400 Highland Ave., Lewistown, PA 17044 Ph: (717) 248-5411 |
News Archive
Johns Hopkins researchers and colleagues have found a previously unrecognized role for tiny hair-like cell structures known as cilia: They help form our sense of touch.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
While many different combinations of genetic traits can cause autism, brains affected by autism share a pattern of ramped-up immune responses, an analysis of data from autopsied human brains reveals. The study, a collaborative effort between Johns Hopkins and the University of Alabama at Birmingham, included data from 72 autism and control brains.
Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).
A RAND Corporation report funded by The Rockefeller Foundation shows that COVID-19 testing can be effectively integrated into K-12 schools' pandemic response plans, helping families and staff feel more comfortable with in-person instruction.
› Verified 1 days ago